- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04664036
Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus (NAFLDIA1)
Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus Obtained Via a Non-invasive Screening Protocol
Nonalcoholic fatty liver disease (NAFLD) is a condition characterized by intrahepatic fat accumulation. It is closely related to insulin resistance. To date, it remains unclear whether NAFLD is common in patients with type 1 diabetes or if NAFLD translates into an increased health burden in this population. Screening for NAFLD is challenging due to the limitations of non-invasive diagnostic tools.
Liver biopsy remains the gold standard but is not suited for routine screening or clinical studies. Therefore, there is a great demand for accurate non-invasive screening tools that can not only diagnose but also stage NAFLD. This study aims to generate a large cohort of thoroughly characterized type 1 diabetes patients screened for NAFLD using multiple non-invasive tools including MRI, ultrasound, controlled attenuation parameter, and score panels. We aim to generate a biobank to promote a research collaboration network in the field of non-invasive diagnosis of NAFLD.
A secondary endpoint is to investigate the potential correlation between the presence of NAFLD and the occurrence of micro-or macrovascular complications in patients with diabetes.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This study aims to characterize and follow a thoroughly characterized cohort of adult type 1 diabetes patients free from secondary liver disease due to excessive alcohol usage, viral hepatitis, alfa-1 antitrypsin deficiency, Wilson's disease or steatogenic or hepatotoxic drug use.
The investigators will screen for NAFLD and fibrosis using multiple non-invasive techniques including
- ultrasound
- controlled attenuation parameter
- fatty liver index
- human steatosis index
- transient elastography
- FIB-4
- NAFLD fibrosis score
- NASH algorithm based on multiple parameters
Subjects will be screened for microvascular and microvascular complications with:
- ECG
- microfilament examination
- 24hour urine collection for microalbuminuria
- serum kidney test (creatinine, eGFR)
- fundoscopy
- peripheral arterial pulsation palpation
The investigators will subsequently thoroughly characterize various metabolic and anthropometric parameters and document any microvascular or macrovascular complications.
The patients will be annually rescreened for both NAFLD-related as cardiovascular variables. Therefore this study will assess the correlation between NAFLD, cardiovascular risk, and type 1 diabetes in a prospective manner.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiekontakt
- Navn: Jonathan Mertens, M.D.
- Telefonnummer: +328217304
- E-mail: jonathan.mertens@uza.be
Undersøgelse Kontakt Backup
- Navn: Rie Braspenning, nurse
- E-mail: rie.braspenning@uza.be
Studiesteder
-
-
Antwerp
-
Edegem, Antwerp, Belgien, 2650
- Rekruttering
- Antwerp University Hospital
-
Kontakt:
- Jonathan Mertens, M.D.
- Telefonnummer: +328217304
- E-mail: jonathan.mertens@uza.be
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Type 1 diabetes
- Adult age
- Informed consent given
Exclusion Criteria:
- Secondary liver disease
- Excess alcohol usage
- Pregnancy
- Use of steatogenic medication
- Active cancer or oncological treatment
- History of organ transplantation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
NAFLD + type 1 diabetes
type 1 diabetes patient with NAFLD on screening
|
ultrasound to check for NAFLD according to Saverymuttu criteria
elastography to compare liver stiffness indices
CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis
the FLI is a score panel designed to screen for NAFLD
the FIB-4 is a score panel designed to screen for significant fibrosis
the NFS is a score panel designed to screen for significant fibrosis
|
noNAFLD + type 1 diabetes
type 1 diabetes patient without NAFLD on screening
|
ultrasound to check for NAFLD according to Saverymuttu criteria
elastography to compare liver stiffness indices
CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis
the FLI is a score panel designed to screen for NAFLD
the FIB-4 is a score panel designed to screen for significant fibrosis
the NFS is a score panel designed to screen for significant fibrosis
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Prevalence of NAFLD in type 1 diabetes: percentage of patients with indices of liver steatosis and/or NASH and/or fibrosis.
Tidsramme: one year
|
Determination of the cross-sectional prevalence of NAFLD in a cohort of type 1 diabetes patient (population size approximately 1000 subjects) according to ultrasound criteria, FLI≥60, HSI≥36, controlled attenuation parameter >215dB/m (M-probe) or ≥250 dB/m (XL probe) and MRI-PDFF >5% hepatocyte steatosis (reference method).
All measures will be performed in a combined and standardized protocol to explore their diagnostic accuracy (see outcome 4).
|
one year
|
Incidence of NAFLD in type 1 diabetes.
Tidsramme: five years
|
Incidence of NAFLD in type 1 diabetes determined by new cases of NAFLD according to ultrasound criteria, FLI≥60, HSI≥36, controlled attenuation parameter >215dB/m (M-probe) or ≥250 dB/m (XL probe) or MRI-PDFF >5% hepatocyte fat infiltration (reference method)
|
five years
|
correlation of NAFLD with microvascular and macrovascular complications in type 1 diabetes mellitus: odds ratio to have prevalent complications in NAFLD and diabetes compared to diabetes without NAFLD
Tidsramme: one year
|
The correlation between indices of microvascular (neuropathy assessed by microfilament test, nephropathy assessed by microalbuminuria rate and retinopathy assessed by fundoscopic criteria) or macrovascular (non-fatal ischemic coronary disease, non-fatal cerebrovascular disease, non-fatal peripheral artery disease, or mortality due to cardiovascular disease) complications will be compared between groups with and without NAFLD as determined by the abovementioned screening tools.
|
one year
|
Association of NAFLD with microvascular and macrovascular complications in type 1 diabetes mellitus: odds ratio to develop in NAFLD and diabetes compared to diabetes without NAFLD in subjects with no prior complications
Tidsramme: five years
|
The association between indices of microvascular (neuropathy assessed by microfilament test, nephropathy assessed by microalbuminuria rate and retinopathy assessed by fundoscopic criteria) or macrovascular (non-fatal ischemic coronary disease, non-fatal cerebrovascular disease, non-fatal peripheral artery disease or mortality due to cardiovascular disease) complications will be assessed between groups with and without NAFLD, but all without prior micro- or macrovascular disease as determined by the abovementioned screening tools.
|
five years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Diagnostic accuracy of non-invasive tools for NAFLD in type 1 diabetes: comparison of AUROC and diagnostic accuracy
Tidsramme: five years
|
The investigators will compare the abovementioned non-invasive tools to diagnose and grade liver steatosis and fibrosis with the predefined gold standard (MRI-PDFF for steatosis and magnetic resonance elastography for fibrosis).
Correlations and agreement statistics will be performed for each index.
Using regression analysis, a new specific algorithm will be developed based on cohort-specific cutoffs.
Using longitudinal data, a prediction score will be determined to predict NAFLD occurrence or NAFLD progression.
|
five years
|
Natural history of NAFLD in type 1 diabetes
Tidsramme: five years
|
Timewise description of the progression of quantitative indices of liver steatosis and fibrosis on the abovementioned tools (ultrasound, score systems, elastography) to assess the natural evolution of NAFLD.
Every year this assay will be performed.
MRI-PDFF will be performed in 5 years as a reference method to mark the five-year follow-up window
|
five years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Christophe De Block, M.D., PhD, Universiteit Antwerpen
- Ledende efterforsker: Sven Francque, M.D., PhD, Universiteit Antwerpen
Publikationer og nyttige links
Generelle publikationer
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7. No abstract available.
- de Vries M, Westerink J, Kaasjager KHAH, de Valk HW. Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020 Dec 1;105(12):3842-53. doi: 10.1210/clinem/dgaa575.
- Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S, Giamberardino MA, Cipollone F, Sutton R, Vettor R, Fedorowski A, Meschi T. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019 Aug 26;16(17):3104. doi: 10.3390/ijerph16173104.
- Ismaiel A, Dumitrascu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne). 2019 Sep 13;6:202. doi: 10.3389/fmed.2019.00202. eCollection 2019.
- De Block CEM, Shivalkar B, Goovaerts W, Brits T, Carpentier K, Verrijken A, Van Hoof V, Parizel PM, Vrints C, Van Gaal LF. Coronary artery calcifications and diastolic dysfunction versus visceral fat area in type 1 diabetes: VISCERA study. J Diabetes Complications. 2018 Mar;32(3):271-278. doi: 10.1016/j.jdiacomp.2017.11.008. Epub 2017 Nov 28.
- Hampson SJ. Nursing interventions for the first three postpartum months. J Obstet Gynecol Neonatal Nurs. 1989 Mar-Apr;18(2):116-22. doi: 10.1111/j.1552-6909.1989.tb00474.x.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 18/32/361
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hjerte-kar-sygdomme
-
Ottawa Hospital Research InstituteAfsluttetStress | Crisis Resource Management (CRM) færdigheder | Advanced Cardiovascular Life Support (ACLS) færdighederCanada
Kliniske forsøg med ultrasound
-
ReCor Medical, Inc.Ikke rekrutterer endnuHjerte-kar-sygdomme | Karsygdomme | Forhøjet blodtryk
-
ReCor Medical, Inc.RekrutteringForhøjet blodtrykTyskland, Holland, Belgien, Frankrig, Monaco, Schweiz, Det Forenede Kongerige
-
Medical University of South CarolinaSouth Carolina Spinal Cord Injury Research FundRekrutteringRygmarvssygdomme | Spinal stenose | Rygmarvsskader | Degeneration af rygsøjlen | Rygmarvskompression | Rygsøjle sygdom | RygmarvsskadeForenede Stater
-
Dr. Linda McLeanOttawa Hospital Research Institute; The Ottawa HospitalTilmelding efter invitation
-
The University of Hong KongAfsluttet
-
The Hospital for Sick ChildrenSunnybrook Health Sciences CentreAfsluttetSmerte | Osteoid Osteom | Godartet knogletumorCanada
-
The University of Hong KongSuspenderetPapillar Thyroid MicrocarcinomHong Kong
-
Fundacion para la Investigacion y Formacion en...AfsluttetULTRASONOGRAFI | PRIMÆRE SUNDHEDSSEKTORSpanien
-
Hospices Civils de LyonAfsluttet